Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 4,773 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HIV Clear all
Completed Phase 2 Interventional

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

NCT00002364
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:25 AM EDT
Not listed Phase 2 Interventional

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

NCT02291809
View directory record Official record
Conditions
HIV/AIDS
Interventions
REMUNE
Biological
Lead sponsor
Immune Response BioPharma, Inc.
Industry
Eligibility
3 Months to 16 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 22, 2026, 11:25 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898
View directory record Official record
Conditions
Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Interventions
Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 22, 2026, 11:25 AM EDT
Completed No phase listed Observational

To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C, Along With Associated Risk Behaviors, in Patients With Severe Mental Illness (SMI).

NCT00007709
View directory record Official record
Conditions
Hepatitis C, HIV Infections, Mental Disorders
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2011 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healing Our Hearts Minds and Bodies: CVD Reduction in Persons With HIV

NCT04025463
View directory record Official record
Conditions
HIV/AIDS, Cardiovascular Risk Factors, Trauma, Psychological
Interventions
HHMB
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Van Nuys, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 22, 2026, 11:25 AM EDT
Active, not recruiting Not applicable Interventional

Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth

NCT05965245
View directory record Official record
Conditions
Depression, HIV Infection
Interventions
Suubi-Mhealth
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 17 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

NCT00000802
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone, Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents

NCT00640653
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Abstinence-only HIV/STD risk-reduction intervention, Safer-sex-only HIV/STD risk-reduction intervention, Long comprehensive HIV/STD risk-reduction intervention, Short comprehensive HIV/STD risk-reduction intervention, Health promotion control intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
662 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)

NCT00933595
View directory record Official record
Conditions
Pulmonary Complications, HIV Infections
Interventions
Smoking Cessation
Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 22, 2026, 11:25 AM EDT
Recruiting No phase listed Observational

Feasibility of HPV Testing With Mail-delivered Sample Collection Kits

NCT07087145
View directory record Official record
Conditions
HPV Infection, HIV Infections, HPV-Related Malignancy
Interventions
Mail-based Saliva Sample Kit, Study-related Surveys
Diagnostic Test · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

NCT00007202
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
4
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

NCT00006145
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease

NCT00002337
View directory record Official record
Conditions
HIV Infections
Interventions
Vesnarinone
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00004855
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Abacavir sulfate, Nevirapine, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
23
States / cities
Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

NCT00004978
View directory record Official record
Conditions
HIV Infections
Interventions
Recombinant interleukin-2 (rIL-2)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
78
States / cities
Los Angeles, California • Mill Valley, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

NCT00000635
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Trifluridine, Bacitracin zinc/Polymyxin B sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Growth Hormone Treatment of Children With HIV-Associated Growth Failure

NCT00006143
View directory record Official record
Conditions
HIV Infections
Interventions
Somatropin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 13 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

NCT03603808
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions
Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
Device · Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

NCT01040091
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF), Efavirenz (EFV), Truvada
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

WHC+ (Women's Health CoOp PLUS)

NCT01497405
View directory record Official record
Conditions
HIV, Sexual Risk, Sexually Transmitted Diseases, Substance Abuse, Violence, Victimization
Interventions
Test, Treat, Retain(TTR) + Women's Health CoOp (WHC), Test, Treat, Retain(TTR) only
Behavioral · Biological
Lead sponsor
RTI International
Other
Eligibility
15 Years to 55 Years · Female only
Enrollment
641 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TMS for Smoking Cessation in PLWHA Cessation in People Living With HIV/AIDS (PLWHA)

NCT04936594
View directory record Official record
Conditions
Smoking Cessation, HIV, Craving
Interventions
iTBS, TMS
Device
Lead sponsor
Gopalkumar Rakesh
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 22, 2026, 11:25 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Transgender Cohort Study of Gender Affirmation and HIV-related Health

NCT03595956
View directory record Official record
Conditions
HIV/AIDS, STI, Gender Dysphoria, Transsexualism, Gender Identity, Depression, Anxiety
Interventions
Medical gender affirmation
Other
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 22, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

MMF for HIV Reservoir Reduction

NCT03262441
View directory record Official record
Conditions
Human Immunodeficiency Virus I Infection
Interventions
Mycophenolate Mofetil 500Mg Tab
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 22, 2026, 11:25 AM EDT